We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Second Line Therapy with Weekly Low-dose Docetaxel for Pretreated Non-Small-Cell Lung Carcinoma Patients: A Multicenter Italian Phase II Study.
- Authors
Ardizzoia, A.; Acquati, M.; Fagnani, D.; Giordano, M.; Visini, M.; Scanni, A.; Quattrone, A.; Fusco, O.; Vergani, C.; Casartelli, C.; Tagliabue, P.; Malugani, F.
- Abstract
Docetaxel is one of the most active drugs in second-line therapy for non-small-cell-lung-carcinoma (NSCLC). The aim of this multicenter study was to evaluate the safety and efficacy of weekly low-dose docetaxel. Forty-two patients with advanced NSCLC pretreated with cisplatinum-based chemotherapy were enrolled. Docetaxel was administered at a dose of 25 mg/m[sup 2] weekly for 12 consecutive weeks. A total of 386 doses were given with a median number of 10 doses per patient (range: 3–12). Treatment showed low incidence of hematologic toxicity and modest non-hematologic toxicity. An episode of grade 4 thrombocytopenia was reported but no episodes of grade 3 or 4 neutropenia. Most frequent non-hematologic toxicities were asthenia and alopecia. Response rate was 10.5% and median survival time (MST) was 12.8 weeks. Weekly treatment with 25 mg/m[sup 2] docetaxel for 12 consecutive weeks appears to be a feasible and active regimen with mild toxicity in heavily pretreated NSCLC patients.
- Subjects
DOCETAXEL; ANTINEOPLASTIC agents; ALKALOIDS; THROMBOCYTOPENIA; CANCER; ASTHENIA; BALDNESS
- Publication
Lung, 2004, Vol 182, Issue 1, p1
- ISSN
0341-2040
- Publication type
Article
- DOI
10.1007/s00408-003-1039-5